Adv Yuval Lazi > Barnea Jaffa Lande & Co. > Tel Aviv, Israel > Lawyer Profile

Barnea Jaffa Lande & Co.
ELECTRA CITY TOWER
58 HARAKEVET ST
TEL AVIV 6777016
Israel

Work Department

Corporate, Mergers and Aquisitions, Technology

Position

uval has significant experience in mergers and acquisitions, with a strong focus on international commercial transactions, private equity, and venture capital investments. He specializes in cross-border M&A for technology companies, representing multinational corporations, VC funds, entrepreneurs, investors, and startups across all stages of growth—from inception and initial funding to exit or IPO.

Yuval provides strategic legal counsel on a wide range of operational matters, including financing, intellectual property, cyber and privacy issues, structural changes, strategic initiatives, and complex corporate and commercial transactions. These include technology transfers, asset and business sales, licensing, and distribution agreements.

He regularly advises numerous startups at various stages of investment, supporting them through fundraising, financing rounds, joint ventures, and exit strategies. In addition, Yuval represents both venture capital and private equity funds, guiding them through their formation and commercial operations, as well as their investments in emerging companies.

Languages

Hebrew, English

Memberships

New York Bar, 2004
Israel Bar Association, 2003

Education

Brunel University ,(LL.B) with Honours, 2001

Lawyer Rankings

Israel > Investment and venture capital funds

Barnea Jaffa Lande & Co. advises a wide range of institutional investors, including investment houses, insurance companies, and private equity, venture capital, and hedge funds, on complex fund structuring and formation. Practice head Roy Engel is renowned for his expertise in fund formation and investment management, frequently representing funds in mergers and acquisitions. Regulatory expert Zvi Gabbay provides guidance to various funds on compliance and regulatory matters, while Yuval Lazi has extensive experience in representing both venture capital and private equity funds in their investment activities.

Israel > Commercial, corporate and M&A

Barnea Jaffa Lande & Co. is a trusted advisor for complex, often cross-border M&A transactions for both Israeli and multinational corporations. Michael Barnea leads the practice, Ariella Dreyfuss handles VC and PE transactions, while Simon Jaffa and Yuval Lazi guide private equity, venture capital, and hedge funds through M&A and investment deals. Ilan Blumenfeld is noted for his expertise in domestic M&A, while Itay Gura has considerable expertise in joint ventures.

Israel > Hi-tech and start-ups

(Leading partners)

Yuval LaziBarnea Jaffa Lande & Co.

Barnea Jaffa Lande & Co. garners praise for its understanding of the ‘unique challenges faced by start-ups’. Highly active in M&A and investment transactions, the team represents a broad mix of start-ups, emerging companies, R&D centres, mature technology corporations and strategic investors. Yuval Lazi is ‘a true partner’ and co-heads the department alongside up-and-coming specialist Itay Gura. High-profile corporate head Michael Barnea and privacy expert Avishay Klein are also noted.

Israel > Intellectual property > Intellectual property: commercial/transactions

The team at Barnea Jaffa Lande & Co. remains a go-to for venture capital funds, prominent startups, and high-profile clients seeking guidance on IP-heavy transactions and other IP-based commercial matters. With a notable emphasis on the high-tech sector, the group is led by complex technology transactions expert Michael Barnea, and includes Yuval Lazi, who is well-versed in various IP matters pertinent to the high-tech realm, and Itay Gura, an experienced advisor of high-tech mergers and acquisitions. Inbar Gorelick specialises in royalties matters, licensing, R&D agreements for a diverse list of clients, and Ariella Dreyfuss  is a key contact for international investors and companies. The practice also comprises Ken Shaked, who focuses on biotech, med-tech, and related industries, leveraging previous experience as a general counsel for pharmaceutical heavyweights.